LBA50 IMbrave152/SKYSCRAPER-14: A phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)

作者：R.S. Finn, A.G. Singal, Ann‐Lii Cheng, B-Y. Ryoo, B. Sangro, D. Li, Josep M. Llovet, Jisu Hong, Jian Zhou, L. Rimassa, M. Kudo, Peter R. Galle, Yuehua Guo, Yasmin Ibrahim, Y Zhang, Christopher Cotter, Mingsheng Huang, X. Wen, Jian‐Bing Fan · 发表于：Annals of Oncology · 年份：2025 · DOI：10.1016/j.annonc.2025.09.062 · 被引用次数：4 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Peptidase Inhibition and Analysis、HER2/EGFR in Cancer Research